uniQure (NASDAQ:QURE) Price Target Lowered to $30.00 at Wells Fargo & Company

uniQure (NASDAQ:QURE) had its target price decreased by Wells Fargo & Company from $35.00 to $30.00 in a research report sent to investors on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biotechnology company’s stock.

A number of other analysts have also issued reports on QURE. StockNews.com raised uniQure to a “sell” rating in a research note on Wednesday, February 5th. HC Wainwright boosted their target price on shares of uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a report on Monday, January 27th. Stifel Nicolaus upped their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Mizuho upped their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $38.89.

uniQure Trading Up 8.9 %

Shares of uniQure stock opened at $13.15 on Friday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The business’s fifty day moving average is $15.05 and its two-hundred day moving average is $9.79. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $640.73 million, a PE ratio of -2.65 and a beta of 0.38.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 26,727 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. The trade was a 4.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the transaction, the chief financial officer now owns 152,372 shares of the company’s stock, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 55,915 shares of company stock valued at $588,112. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Voloridge Investment Management LLC acquired a new position in uniQure in the 4th quarter worth $3,129,000. Woodline Partners LP acquired a new position in shares of uniQure in the fourth quarter worth about $2,484,000. Two Sigma Advisers LP boosted its holdings in uniQure by 1.4% in the fourth quarter. Two Sigma Advisers LP now owns 756,900 shares of the biotechnology company’s stock valued at $13,367,000 after purchasing an additional 10,400 shares during the last quarter. Two Sigma Investments LP grew its stake in uniQure by 9.2% during the 4th quarter. Two Sigma Investments LP now owns 878,884 shares of the biotechnology company’s stock valued at $15,521,000 after purchasing an additional 73,988 shares in the last quarter. Finally, Stempoint Capital LP purchased a new stake in uniQure during the 4th quarter worth approximately $1,589,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.